文献速递牙周病

重度慢性牙周炎不同抗生素方案的疗效:一项1年随机试验

Different antibiotic protocols in the treatment of severe chronic periodontitis: A 1-year randomized trial.
PubMed 文献 · J Clin Periodontol · 2017-07-26

研究纳入109例重度广泛性慢性牙周炎受试者,随机接受单纯龈下刮治和根面平整(SRP)或联合甲硝唑(MTZ)250或400 mg加阿莫西林(AMX)500 mg每日三次,疗程7或14天,随访1年。1年时,14天疗程组达临床终点比例高于7天疗程组和单纯SRP组,14天疗程是达临床终点的唯一显著预测因素,不良事件频率组间无差异。

要点

  • 14天MTZ+AMX联合SRP组1年临床终点达标率高于7天疗程组和单纯SRP组。
  • 14天MTZ+AMX是1年达临床终点的唯一显著预测因素(OR 5.26)。
  • 各治疗组不良事件频率无显著差异。

核心结论

  • 辅助使用甲硝唑400或250 mg加阿莫西林500 mg每日三次、疗程14天,在重度广泛性慢性牙周炎治疗中较单纯SRP提供有统计学显著性和临床相关性的额外获益。
  • 7天方案在该人群中额外获益较不明显。

研究设计与样本

  • 随机对照试验,纳入109例重度广泛性慢性牙周炎受试者,随机接受单纯SRP或联合MTZ 250或400 mg加AMX 500 mg每日三次,疗程7或14天,随访1年。

主要发现

  • 1年时,接受AMX+MTZ 250 mg或400 mg联合14天者分别有61.9%和63.6%达到临床终点(探诊深度≥5 mm的位点≤4个),而接受MTZ 250或400 mg联合7天者为31.8%(p < .05),单纯SRP组为13.6%(p < .05)。
  • 14天MTZ+AMX是1年达临床终点的唯一显著预测因素(OR 5.26;95% CI 2.3-12.1;p = .0000)。
  • 不良事件频率在各治疗组间无差异(p > .05)。

关键数值与推荐

  • 临床终点定义为探诊深度≥5 mm的位点≤4个。
  • 14天MTZ+AMX达临床终点的OR为5.26(95% CI 2.3-12.1,p = .0000)。

临床怎么用

  • 作者认为,在重度广泛性慢性牙周炎治疗中,辅助使用MTZ 400或250 mg加AMX 500 mg每日三次、疗程14天较单纯SRP有统计学显著性和临床相关性的额外获益。
  • 作者指出,7天方案在该人群中的额外获益较不明显。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To evaluate the clinical effects of different dosages of metronidazole (MTZ) and durations of MTZ + amoxicillin (AMX) in the treatment of generalized chronic periodontitis (GChP). MATERIAL AND METHODS: Subjects with severe GChP were randomly assigned to receive scaling and root planing (SRP)-only, or combined with 250 or 400 mg of MTZ + AMX (500 mg) thrice a day (TID), for 7 or 14 days. Subjects were monitored for 1 year. RESULTS: One hundred and nine subjects were enrolled. At 1 year, 61.9% and 63.6% of the subjects receiving AMX + 250 or 400 mg of MTZ for 14 days, respectively, reached the clinical endpoint for treatment (≤4 sites with probing depth ≥5 mm), against 31.8% of those taking 250 or 400 mg of MTZ for 7 days (p < .05) and 13.6% of those receiving SRP-only (p < .05). Fourteen days of MTZ + AMX was the only significant predictor of subjects reaching the clinical endpoint at 1 year (OR, 5.26; 95% CI, 2.3-12.1, p = .0000). The frequency of adverse events did not differ among treatment groups (p > .05). CONCLUSION: The adjunctive use of 400 or 250 mg of MTZ plus 500 mg of AMX/TID/14 days offers statistically significant and clinically relevant benefits over those achieved with SRP alone in the treatment of severe GChP. The added benefits of the 7-days regimen in this population were less evident. (ClinicalTrials.gov NCT02735395).

来源:J Clin Periodontol,查看原文。版权归原作者所有。

引用

  1. Borges I, Faveri M, Figueiredo LC, et al. Different antibiotic protocols in the treatment of severe chronic periodontitis: A 1-year randomized trial. J Clin Periodontol. 2017. PMID: 28303587. doi:10.1111/jcpe.12721

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。